Is Fabino Enter overvalued or undervalued?

As of 17 September 2025, the valuation grade for Fabino Enter has moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 5.35, an EV to EBIT of 6.75, and a ROE of 3.03%.
In comparison to its peers, Fabino Enter's PE ratio of 5.35 is significantly lower than Sun Pharma's 33.91 and Divi's Lab's 69.72, both categorized as expensive and very expensive, respectively. This suggests that while Fabino Enter is overvalued, it is relatively cheaper than some of its peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -22.55% compared to the Sensex's 5.83%, reinforcing the notion of overvaluation.